Abeona acquires Ellodi's APT-1011 (ABO-801) for $20M stock plus up to $60M milestones; raises $30M PIPE

ABEONA THERAPEUTICS INC.

Acquired APT-1011 (renamed ABO-801), a once-daily oral fluticasone propionate ODT for eosinophilic esophagitis; $20M paid in 4,494,383 ABEO shares, no upfront cash.
Ellodi eligible for $30M on FDA NDA approval and up to $30M in sales milestones, plus low-to-mid-teens royalties; 4,494,383 shares locked up 1/3 at 6, 12, 18 months.
Private placement: 6,400,000 shares at $3.75 plus pre-funded warrants for 1,600,043 shares at $3.7499, ~$30M gross; investors include Nantahala, TPG, Perceptive; Morgan Stanley agent.
ABO-801 holds FDA Orphan Drug and Fast Track designations; two completed Phase 3 trials (361 patients) missed the co-primary symptom endpoint but showed significant endoscopic gains.
Phase 3 trial planned to start Q2 2027, topline by end-2028; ~360,000 patients in the U.S. diagnosed with EoE.

item 1.01 item 2.01 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.